METHODS FOR TREATING DIABETES AND / OR IMPROVING SURVIVAL OF PANCREATIC ISLANDS AFTER TRANSPLANTATION

摘要

1. A method of treating and / or preventing diabetes, comprising administering to a patient in need thereof an effective amount of a specific expression inhibitor or function of SMAD7.2. The method of claim 1, wherein the diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes and gestational diabetes. A method for improving the survival of an organ and / or cells after transplantation, comprising administering to a patient in need thereof an effective amount of a specific expression inhibitor or function of SMAD7.4. The method of claim 3, wherein the cell is a pancreatic islet cell. The method according to any one of paragraphs. 1-4, in which the specific inhibitor of expression or function of SMAD7 is an antisense oligonucleotide to SMAD7.6. The method of claim 5, wherein the SMAD7 antisense oligonucleotide comprises an oligonucleotide selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 , SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.7. The method of claim 5, wherein the SMAD7 antisense oligonucleotide comprises SEQ ID NO: 5 or SEQ ID NO: 9.8. The method of claim 5, wherein the SMAD7 antisense oligonucleotide comprises SEQ ID NO: 6 or SEQ ID NO: 10.9. The method of claim 5, wherein the SMAD7 antisense oligonucleotide is administered parenterally. The method of claim 9, wherein the SMAD7 antisense oligonucleotide is administered subcutaneously. The method according to any one of paragraphs. 1-4, comprising the introduction of a pharmaceutical composition comprising an antisense oligonucleotide to SMAD7 and a pharmaceutically acceptable carrier. The method of claim 11, wherein the SMAD7 antisense oligonucleotide is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.13. The method of claim 11, wherein the SMAD7 antisense oligonucleotide comprises SEQ ID NO: 5 or SEQ ID NO: 9.14. The method of claim 11, wherein the SMAD7 antisense oligonucleotide comprises SEQ ID NO: 6 or SEQ ID NO: 10.15. The method of claim 11, wherein the pharmaceutical composition is administered subcutaneously.